<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000706.v1.p1" parentStudy="phs000706.v1.p1" createDate="2014-01-22" modDate="2014-01-22">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Barry S. Taylor, PhD</td><td>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>David B. Solit, MD</td><td>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</td></tr>
		<tr><td>Co-Investigator</td><td>John H.J. Petrini, PhD</td><td>Memorial Sloan-Kettering Cancer Center, New York, NY USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>RAD50 Hypomorphism as Basis for Response to Chemotherapy</StudyNameEntrez>
	<StudyNameReportPage>Genome Sequencing Reveals That RAD50 Hypomorphism Results in Enhanced Sensitivity to Checkpoint Kinase Inhibition Combined with Chemotherapy</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Outlier analyses represent a versatile method to identify predictive biomarkers of response to both targeted agents and chemotherapy. We performed whole genome sequencing (WGS) of tumor and germline blood from a patient with metastatic small cell carcinoma of the ureter who experienced a durable complete response to a combination of irinotecan plus AZD7762, a checkpoint kinase inhibitor. The patient initially had resection of the ureter followed by metastatic recurrence within the kidney and lymph nodes and underwent nephrectomy with lymph node dissection. Through WGS of tissue from the second surgery, we detected a hypomorphic L1237F mutation within RAD50, a component of the Mre11 double strand break repair complex, which resulted in heightened sensitivity to the combination of checkpoint inhibition and clastogenic chemotherapy. We validated the WGS findings using a combination of an exon capture assay and validation in model systems. The tumor samples sequenced by exon capture were derived from tissue taken from both the initial and second surgeries.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="22923433"/>
		</Publication>
		<Publication>
			<Pubmed pmid="23897969"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21252998"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18790776"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22585170"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22923433"/>
		</Publication>
		<Publication>
			<Journal authors="Ho AL, Bendell JC, Cleary JM, Schwartz GK, Burris HA, Oakes P, Agbo F, Barker PN, Senderowicz AM, Shapiro G" title="Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors" journal="Journal of Clinical Oncology, 2011; 29:suppl abstract 3033"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Ureteral Neoplasms"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Barry S. Taylor, PhD</AttName>
			<Institution>Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>David B. Solit, MD</AttName>
			<Institution>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>John H.J. Petrini, PhD</AttName>
			<Institution>Memorial Sloan-Kettering Cancer Center, New York, NY USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-MDS" longName="General Research Use (MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000706.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000706.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000706.v1.p1" FileName="eNCI_0174_DUC_7.5.2013.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (MDS)</ConsentName>
        <ConsentAbbrev>GRU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
